Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares, rose in value, with the stock price up by 3.21% to the previous day’s close as strong demand from buyers drove the stock to $1.93.
Actively observing the price movement in the last trading, the stock closed the session at $1.87. Referring to stock’s 52-week performance, its high was $16.26, and the low was $1.61. On the whole, ZNTL has fluctuated by 14.88% over the past month.
With the market capitalization of Zentalis Pharmaceuticals Inc currently standing at about $137.55 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ZNTL’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ZNTL currently trading nearly -11.23% and -20.26% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 40.24, while the 7-day volatility ratio is showing 9.88% which for the 30-day chart, stands at 11.50%. Furthermore, Zentalis Pharmaceuticals Inc (ZNTL)’s beta value is 1.75, and its average true range (ATR) is 0.23.
A comparison of Zentalis Pharmaceuticals Inc (ZNTL) with its peers suggests the former has fared considerably weaker in the market. ZNTL showed an intraday change of 3.21% in last session, and over the past year, it shrunk by -87.37%%. Additionally, there is a gain of 3.39%% for Rogers Corp. (ROG) in last trading while the stock has seen an overall depriciation of -29.38%% over the past year.
Data on historical trading for Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) indicates that the trading volumes over the past 3 months, they’ve averaged 1.89 million. According to company’s latest data on outstanding shares, there are 71.15 million shares outstanding.
Nearly 24.81% of Zentalis Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 87.48% of the company’s shares. The stock has fallen by -36.30% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ZNTL stock heading into the next quarter.
